ES2171360B1 - Vacuna para la proteccion de animales frente a la leishmania. - Google Patents

Vacuna para la proteccion de animales frente a la leishmania.

Info

Publication number
ES2171360B1
ES2171360B1 ES200100402A ES200100402A ES2171360B1 ES 2171360 B1 ES2171360 B1 ES 2171360B1 ES 200100402 A ES200100402 A ES 200100402A ES 200100402 A ES200100402 A ES 200100402A ES 2171360 B1 ES2171360 B1 ES 2171360B1
Authority
ES
Spain
Prior art keywords
vaccine
protein
infantum
protection
immunogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100402A
Other languages
English (en)
Other versions
ES2171360A1 (es
Inventor
Rodriguez De La Vera V Larraga
Aseguinolaza Gloria Gonzalez
Hernandez Juan Antoni Castillo
Curdi Javier Lucientes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Laboratorios Hipra SA
Universidad de Zaragoza
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Laboratorios Hipra SA
Universidad de Zaragoza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Laboratorios Hipra SA, Universidad de Zaragoza filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES200100402A priority Critical patent/ES2171360B1/es
Priority to ES200102057A priority patent/ES2172482B1/es
Priority to AT02702414T priority patent/ATE439858T1/de
Priority to PCT/ES2002/000077 priority patent/WO2002066054A1/es
Priority to PT02702414T priority patent/PT1371375E/pt
Priority to ES02702414T priority patent/ES2334493T3/es
Priority to DE60233391T priority patent/DE60233391D1/de
Priority to EP02702414A priority patent/EP1371375B1/en
Priority to US10/468,618 priority patent/US8986711B2/en
Publication of ES2171360A1 publication Critical patent/ES2171360A1/es
Application granted granted Critical
Publication of ES2171360B1 publication Critical patent/ES2171360B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vacuna para la protección de animales frente a Leishmania. La vacuna comprende una cantidad terapéuticamente efectiva de (i) la proteína P36 de Leishmania infantum o de un fragmento inmunogénico de la misma, y, opcionalmente, un compuesto estimulador de la producción de una respuesta inmune celular de tipo Th1, o (ii) un sistema de expresión de la proteína P36 de L. infantum o de un fragmento inmunogénico de la misma, que comprende, una secuencia de ADN que codifica la proteína P36 de L. infantum o un fragmento inmunogénico de la misma, y, opcionalmente, una secuencia de ADN que codifica un compuesto co- estimulador capaz de estimular la producción de una respuesta inmune celular de tipo Th1. El sistema de expresión puede ser un virus Vaccinia recombinante. La vacuna es útil para prevenir leishmaniasis en animales.
ES200100402A 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania. Expired - Fee Related ES2171360B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200100402A ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.
ES200102057A ES2172482B1 (es) 2001-02-21 2001-09-12 Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".
PCT/ES2002/000077 WO2002066054A1 (es) 2001-02-21 2002-02-21 Vacuna para la protección de animales frente a leishmania
PT02702414T PT1371375E (pt) 2001-02-21 2002-02-21 Vacina para a protecção de animais contra a leishmaníase âmbito técnico
AT02702414T ATE439858T1 (de) 2001-02-21 2002-02-21 Vakzine zum schutz von tieren gegen leishmania
ES02702414T ES2334493T3 (es) 2001-02-21 2002-02-21 Vacuna para la proteccion de animales frente a leishmania.
DE60233391T DE60233391D1 (de) 2001-02-21 2002-02-21 Vakzine zum schutz von tieren gegen leishmania
EP02702414A EP1371375B1 (en) 2001-02-21 2002-02-21 Vaccine to protect animals against leishmania
US10/468,618 US8986711B2 (en) 2001-02-21 2002-02-21 Vaccine to protect animals against leishmania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100402A ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.

Publications (2)

Publication Number Publication Date
ES2171360A1 ES2171360A1 (es) 2002-09-01
ES2171360B1 true ES2171360B1 (es) 2003-12-16

Family

ID=8496822

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200100402A Expired - Fee Related ES2171360B1 (es) 2001-02-21 2001-02-21 Vacuna para la proteccion de animales frente a la leishmania.
ES200102057A Expired - Fee Related ES2172482B1 (es) 2001-02-21 2001-09-12 Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES200102057A Expired - Fee Related ES2172482B1 (es) 2001-02-21 2001-09-12 Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Country Status (2)

Country Link
US (1) US8986711B2 (es)
ES (2) ES2171360B1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313807B1 (es) * 2005-07-30 2009-12-23 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.

Also Published As

Publication number Publication date
ES2172482B1 (es) 2004-12-01
US20040156866A1 (en) 2004-08-12
ES2171360A1 (es) 2002-09-01
ES2172482A1 (es) 2003-07-16
US8986711B2 (en) 2015-03-24

Similar Documents

Publication Publication Date Title
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
HUS1500047I1 (hu) Rekombináns vakcina West Nile vírus ellen
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
ATE517184T1 (de) Hcv ns3/4a kodierende nukleinsäure
AR036793A1 (es) Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante
DK1290160T3 (da) Humane Pellino-polypeptider
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
DE60332425D1 (de) 5t4-antigen-peptidepitope der mhc klasse ii
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
ATE234628T1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
DE50010240D1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
ES2171360B1 (es) Vacuna para la proteccion de animales frente a la leishmania.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ATE378351T1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
WO2004082596A3 (en) Yersinia species compositions
NO20051840L (no) IHNV G-protein til immunstimulering.
AR027443A1 (es) MUTANTES DE EHV gM-NEGATIVOS
DE50304603D1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020901

Kind code of ref document: A1

Effective date: 20020901

FG2A Definitive protection

Ref document number: 2171360B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20190521

FD2A Announcement of lapse in spain

Effective date: 20190604